New Delhi, 17 June (IANS). According to a report released on Tuesday, in May, the Indian Pharma Market (IPM) increased by 6.9 percent on an annual basis, which was recorded due to strong performance in cardiac, respiratory and anti-diabetes therapy.
The growth rate of Indian companies in May was 6.6 percent, while multinational companies were growing 8.4 percent.
According to the report of Motilal Oswal Financial Services Limited, the growth rate of acute therapy in May was 5 percent, which is the second consecutive month, when the growth rate was slow on an annual basis.
The IPM hike for 12 months ended in May contributed 4.2 percent of the price on an annual basis, 2.3 percent of the new launch and 1.1 percent of the quantity hike.
Indian pharma companies had an 83 percent stake in IPM till May this year, while the remaining stake was with multinational pharma companies (MNCs).
Out of the top 20 pharma companies, on an annual basis against IPM, JB Cam recorded 11.6 percent, Glenmark 11.8 percent, Ajanta recorded a high growth rate of 10.6 percent.
Ajanta performed better than IPM due to a strong double -digit increase in major medicine such as anti -diabetic/ophl.
JB Chemicals performed better than IPM due to strong performance in cardiac/opthal/anti -parasitic.
The report stated that on MAT basis, the industry registered an increase of 7.6 percent on an annual basis.
In May, chronic therapy saw an increase of 10 percent on an annual basis, while acute therapy saw an increase of 5 percent on an annual basis.
Meanwhile, according to experts at India Ratings, India’s pharmaceutical industry is on the rate of 7.8 percent on an annual basis due to strong demand and new products in April 2025.
The country’s pharma sector is now third in terms of quantity globally and 14th in terms of value and the country contributes up to 20 percent to the world’s drug supply.
The Indian Pharma industry’s turnover has reached Rs 4,17,345 crore in 2023-24, which has been growing at a rate of more than 10 percent in a year on a annual basis for the last five years.
-IANS
SKT/
